SK BioscienceSK바이오사이언스
302440 · KOSPI · ₩302440 · SK바이오사이언스
Broker reports
| Date | Broker | Report | Rating | Target | Change | Upside | Since publish | Read |
|---|---|---|---|---|---|---|---|---|
| Oct 6 | Heungkuk Securities | [Pharma/Bio/Cosmetics] SK Bioscience - Expectations for PCV Blockbuster | — | — | — | −13.6% | Read ↗ |
Calculated by JONBUR from publicly available broker reports. Reports belong to their publishers. Not financial advice. Includes brokers that publish research publicly; some brokers' reports are client-only and not included.
AI summary of public information
An AI summary of the public information on this company: filed financial statements, filings, prices and news headlines. It doesn't use broker reports; their targets and estimates are shown above.
SK Bioscience remains loss-making on a trailing basis, and its shares are down sharply over the past year.
Trailing twelve-month revenue to H1 2026 is about ₩659B, but operating income is roughly -₩131B and net income about -₩85B. The share price of ₩32,000 sits near its 52-week low of ₩31,500 and well below the high of ₩61,300, giving a market cap of about ₩2.5T.
What stands out
- Revenue jumped 143.5% in 2025 to about ₩651B after falling in 2023 and 2024, but operating losses persisted at about -₩124B.
- Trailing operating margin is -19.9% and net margin -12.8%, with free cash flow of about -₩135B.
- Borrowings of about ₩528B exceed cash of about ₩130B, and liabilities are 48.6% of equity.
- Price returns are -10.5% over one month, -8.2% over three months and -34.9% over one year; no dividend is paid.
- Recent filings include a half-year report, preliminary earnings, a major sales or supply contract in June, and an IR event today; news covers the Inics acquisition for flu and Ebola vaccines and AI use in flu vaccine production.
What to watch
- Next results and whether operating losses narrow from the trailing figures of about -₩131B.
- Debt load of about ₩528B against limited cash, and free cash flow of about -₩135B.
- Whether the Inics acquisition and new contracts translate into revenue; the data does not provide forecasts.
Data as of Oct 26, 2026 · written 3d ago
This is not financial advice.
Also known as: SK Bioscience / SK바이오사이언스 / 302440 / KRX:302440
Source: KRX statistical information